Nocturnal circulating tumor cells: The ultimate selective filter in cancer progression?

Thomas, Frédéric; Dujon, Antoine; Újvári, Beáta; Alix‐Panabières, Catherine

doi:10.1016/j.medj.2022.07.005

Cited by 1 publication

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, recent data suggest that the release and survival of CTCs in the circulation undergoes circadian changes, 81 82 which might have also important implications for the clinical use of CTCs as biomarkers. The future will tell us whether we identified the ultimate selective filter in cancer progression-CTCs releasing during the rest phase 83 -and more importantly, whether this nocturnal CTC dissemination is due to the role of sleep or circadian cycle. 84 For the clinical implementation of CTCs as liquid biopsy marker, the harmonization and technical validation of the plethora of different technologies is essential.…”

Section: Discussionmentioning

confidence: 99%

Crucial roles of circulating tumor cells in the metastatic cascade and tumor immune escape: biology and clinical translation

Pantel

Alix‐Panabières

2022

J Immunother Cancer

Self Cite

View full text Add to dashboard Cite

Cancer-related deaths are mainly caused by metastatic spread of tumor cells from the primary lesion to distant sites via the blood circulation. Understanding the mechanisms of blood-borne tumor cell dissemination by the detection and molecular characterization of circulating tumor cells (CTCs) in the blood of patients with cancer has opened a new avenue in cancer research. Recent technical advances have enabled a comprehensive analysis of the CTCs at the genome, transcriptome and protein level as well as first functional studies using patient-derived CTC cell lines. In this review, we describe and discuss how research on CTCs has yielded important insights into the biology of cancer metastasis and the response of patients with cancer to therapies directed against metastatic cells. Future investigations will show whether CTCs leaving their primary site are more vulnerable to attacks by immune effector cells and whether cancer cell dissemination might be the ‘Achilles heel’ of metastatic progression. Here, we focus on the lessons learned from CTC research on the biology of cancer metastasis in patients with particular emphasis on the interactions of CTCs with the immune system. Moreover, we describe and discuss briefly the potential and challenges for implementing CTCs into clinical decision-making including detection of minimal residual disease, monitoring efficacies of systemic therapies and identification of therapeutic targets and resistance mechanisms.

show abstract

Section: Discussionmentioning

confidence: 99%